CSL Makes US$11.7 Billion Offer for Switzerland's Vifor Pharma -- Update

   By Stuart Condie 
 

SYDNEY--Australian biopharmaceutical company CSL Ltd. has made an all-cash offer for Vifor Pharma Ltd. that values the Swiss pharmaceutical developer's equity at US$11.7 billion.

CSL on Tuesday said it would partially fund the acquisition with a fully underwritten 6.3 billion-Australian-dollar (US$4.49 billion) institutional share placement and a share purchase plan of up to A$750 million. It will also tap US$6.0 billion in existing cash and a combination of new and existing debt.

Vaccine and blood-product maker CSL said it made a public tender offer of US$179.25 a share, representing a 40% premium to the 60-day volume-weighted average price on Dec. 1. The offer was unanimously recommended by Vifor's directors and Patinex AG, Vifor Pharma's largest shareholder with a 23.2% stake, agreed to tender its shares, CSL said.

The tender offer is subject to a minimum acceptance rate of 80% and is expected to commence around Jan. 18, CSL said.

Vifor's portfolio, focused on renal disease and iron deficiency, will complement CSL's existing therapeutic focus areas, while the Australian company's global reach, R&D capabilities and resources will augment the delivery of Vifor Pharma products.

"Vifor Pharma will also expand our presence in the rapidly growing nephrology market, while giving us the opportunity to leverage our complementary scientific expertise," CSL Chief Executive and Managing Director Paul Perreault said.

If the transaction goes through, it will be immediately EPS-accretive and diversify CSL's revenue base, Mr. Perreault said. CSL said it also identified US$75 million run-rate pretax cost synergies over the first three years of ownership.

Investment bank Citi said last week that any move for Vifor would likely be EPS-accretive, given CSL trades at a significantly higher multiple than Vifor, which develops, manufactures and markets iron-deficiency products.

Vifor has a market capitalization of 9.11 billion Swiss francs (US$9.88 billion) after its shares surged 18% on Monday's confirmation of talks with CSL.

CSL's market capitalization is A$135.46 billion (US$96.60 billion). Shares in CSL, the second-largest ASX-listed company by market capitalization, didn't trade on Tuesday, after they were placed in a trading halt until Thursday.

Write to Stuart Condie at [e-mail]

(END) Dow Jones Newswires

December 14, 2021 01:34 ET (06:34 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.